AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3307584 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin (0.2 U/kg body weight)
Number of subjects: 10
Study 3307584 — intervention group
Group type: COMPARATOR
Intervention: Purified pork insulin (0.2 U/kg body weight)
Number of subjects: 10
Study 3307584 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin
Number of subjects: 10
Study 3307584 — intervention group
Group type: COMPARATOR
Intervention: Purified pork insulin
Number of subjects: 10
Study 31992249 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and sedentary time in South Asian and white British children
Number of subjects: 342
Study 31992249 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 342
Study 31992249 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekends vs weekdays
Number of subjects: 342
Study 31992249 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring vs winter
Number of subjects: 342
Study 31992249 — intervention group
Group type: EXPERIMENTAL
Intervention: High birth weight
Number of subjects: 342
Study 31992249 — intervention group
Group type: EXPERIMENTAL
Intervention: Older mothers
Number of subjects: 342
Study 31992249 — intervention group
Group type: EXPERIMENTAL
Intervention: Income levels
Number of subjects: 342
Study 31992249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 342
Study 30403574 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg subcutaneously every 2 weeks)
Number of subjects: 18924
Study 30403574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 30403574 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 26981608 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive oral health care (oral health examination, oral health education, topical fluoride application, dental treatment)
Number of subjects: 357
Study 26981608 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral health examination only)
Number of subjects: 357
Study 26981608 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive oral health care
Number of subjects: 357
Study 26102260 — intervention group
Group type: EXPERIMENTAL
Intervention: Kettlebell training (KB) group (n = 9)
Number of subjects: 17
Study 26102260 — intervention group
Group type: COMPARATOR
Intervention: Circuit weight-training (CWT) control group (n = 8)
Number of subjects: 17
Study 24081999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports-related TBI admissions
Number of subjects: 3878
Study 24081999 — intervention group
Group type: COMPARATOR
Intervention: ED visits for sports-related TBIs
Number of subjects: 3878
Study 20580423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg) and Vitamin E (400 IU) daily until delivery
Number of subjects: 762
Study 20580423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 762
Study 18648200 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) treatment, mean dose 158 mg, duration at least 3 months
Number of subjects: 96
Study 18648200 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) treatment
Number of subjects: 96
Study 16848374 — intervention group
Group type: EXPERIMENTAL
Intervention: Konstanz method of moral dilemma discussion (KMDD), 90 minutes once a week for 6 weeks
Number of subjects: 83
Study 16848374 — intervention group
Group type: COMPARATOR
Intervention: Control group discussion on non-ethical topics, once a week for 6 weeks
Number of subjects: 83
Study 14717538 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic athletes
Number of subjects: 140
Study 14717538 — intervention group
Group type: COMPARATOR
Intervention: Physical education female students
Number of subjects: 140
Study 14717538 — intervention group
Group type: COMPARATOR
Intervention: Non-sportive women
Number of subjects: 140
Study 11005755 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of lidocaine
Number of subjects: 6
Study 11005755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8927673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 162
Study 8927673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 1832607 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide monohydrate, 1200 mg daily three days before surgery, tapering to 900 mg daily postoperatively
Number of subjects: 32
Study 6624525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimeglumine iocarmate (Dimerex)
Number of subjects: 374
Study 6624525 — intervention group
Group type: COMPARATOR
Intervention: Conray Meglumin
Number of subjects: 374
Study 6624525 — intervention group
Group type: COMPARATOR
Intervention: Sodium‐calcium‐meglumine metrizoate (Isopaque Cerebral)
Number of subjects: 374
Study 30249195 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (300 mg)
Number of subjects: 2400
Study 30249195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study 27259709 — intervention group
Group type: EXPERIMENTAL
Intervention: EP217609 (1, 3, or 10 mg)
Number of subjects: 20
Study 27259709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24977250 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone blocks (AB group)
Number of subjects: 40
Study 24977250 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine bone blocks (XB group)
Number of subjects: 40
Study 23311022 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stop cholecystectomy clinics
Number of subjects: 0
Study 23311022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean thinking principles
Number of subjects: 0
Study 20071642 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber intake group (highest 10%)
Number of subjects: 543
Study 20071642 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fiber intake group (lowest 10%)
Number of subjects: 543
Study 20071642 — intervention group
Group type: EXPERIMENTAL
Intervention: Average fiber intake group (middle 80%)
Number of subjects: 543
Study 20071642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 264)
Number of subjects: 543
Study 20071642 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 543
Study 20071642 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall fiber intake
Number of subjects: 543
Study 17324094 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program focused on mammography delivered by a lay health advisor
Number of subjects: 775
Study 17324094 — intervention group
Group type: COMPARATOR
Intervention: Physician letter/brochure focusing on Pap tests
Number of subjects: 775
Study 17324094 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group for developing cervical cancer
Number of subjects: 775
Study 17324094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group for developing cervical cancer
Number of subjects: 775
Study 16392983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 16392983 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 0
Study 16392983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and interpersonal psychotherapy
Number of subjects: 0
Study 12080869 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Glasgow Outcome Scale (GOSE)
Number of subjects: 61
Study 12080869 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Status Examination (FSE)
Number of subjects: 61
Study 10458260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 24
Study 10458260 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 24
Study 8541734 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Senning procedure (group 2)
Number of subjects: 10
Study 8541734 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (group 1)
Number of subjects: 10
Study 8541734 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study 1975780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (2 X 10 mg)
Number of subjects: 24
Study 1975780 — intervention group
Group type: COMPARATOR
Intervention: Captopril (3 X 25 mg)
Number of subjects: 24
Study 394864 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 cycles of adjuvant CMF
Number of subjects: 325
Study 394864 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of adjuvant CMF
Number of subjects: 325
Study 30091141 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐Wire Reciproc
Number of subjects: 20
Study 30091141 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Blue
Number of subjects: 20
Study 30091141 — intervention group
Group type: COMPARATOR
Intervention: M‐Wire Reciproc and Reciproc Blue (combined)
Number of subjects: 20
Study 27984226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (20 mL 2% lidocaine with epinephrine)
Number of subjects: 204
Study 27984226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL normal saline)
Number of subjects: 204
Study 26367003 — intervention group
Group type: EXPERIMENTAL
Intervention: 1μg LPS
Number of subjects: 15
Study 26367003 — intervention group
Group type: EXPERIMENTAL
Intervention: 10μg LPS
Number of subjects: 15
Study 26367003 — intervention group
Group type: EXPERIMENTAL
Intervention: 30μg LPS
Number of subjects: 15
Study 26367003 — intervention group
Group type: EXPERIMENTAL
Intervention: 100μg LPS
Number of subjects: 15
Study 26367003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24015696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/Veggie Juice Powder (FV)
Number of subjects: 75
Study 24015696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/Veggie/Berry Juice Powder (FVB)
Number of subjects: 75
Study 24015696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 75
Study 24015696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/Veggie Juice Powder (FV) and Fruit/Veggie/Berry Juice Powder (FVB)
Number of subjects: 75
Study 21273491 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin requirements during high altitude trekking
Number of subjects: 8
Study 21273491 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose levels during high altitude trekking
Number of subjects: 8
Study 21273491 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin doses at altitudes >5,000 m
Number of subjects: 8
Study 21273491 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose levels at altitudes >5,000 m
Number of subjects: 8
Study 21273491 — intervention group
Group type: EXPERIMENTAL
Intervention: AMS scores at altitudes >5,000 m
Number of subjects: 8
Study 21273491 — intervention group
Group type: COMPARATOR
Intervention: Energy expenditure and AMS symptoms comparison
Number of subjects: 8
Study 19190034 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 88
Study 19190034 — intervention group
Group type: COMPARATOR
Intervention: Brief supportive therapy
Number of subjects: 88
Study 17080587 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal continuous hormone replacement therapy (HRT) with estradiol 50 microg/day and norethisterone acetate 140 microg/day (Estalis)
Number of subjects: 406
Study 17080587 — intervention group
Group type: COMPARATOR
Intervention: Oral hormone replacement therapy (HRT) with estradiol 2 mg and norethisterone acetate 1 mg (Kliogest)
Number of subjects: 406
Study 14769753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized opioids (morphine, hydromorphone)
Number of subjects: 65
Study 14769753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 65
Study 11443567 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin and ibuprofen
Number of subjects: 52
Study 11443567 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble tumor necrosis factor receptor
Number of subjects: 52
Study 11443567 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble interleukin-1 receptor
Number of subjects: 52
Study 9446349 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients operated for malignant neoplasm
Number of subjects: 57
Study 9446349 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with inflammatory changes and purulent complications
Number of subjects: 57
Study 9446349 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients operated from other indications
Number of subjects: 57
Study 9446349 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy volunteers
Number of subjects: 57
Study 7969244 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial action myoclonus patients
Number of subjects: 17
Study 7969244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OPCA without facial action myoclonus
Number of subjects: 17
Study 7969244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pure cerebellar cortical atrophy
Number of subjects: 17
Study 7969244 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers (control)
Number of subjects: 17
Study 2958817 — intervention group
Group type: EXPERIMENTAL
Intervention: Depilatory agent (group II)
Number of subjects: 100
Study 2958817 — intervention group
Group type: COMPARATOR
Intervention: Shaving (group I)
Number of subjects: 100
Study 29669668 — intervention group
Group type: EXPERIMENTAL
Intervention: GSP301 (olopatadine 665 μg - mometasone 50 μg)
Number of subjects: 30
Study 29669668 — intervention group
Group type: COMPARATOR
Intervention: MF-sponsor (mometasone 50 μg)
Number of subjects: 30
Study 29669668 — intervention group
Group type: COMPARATOR
Intervention: MF (mometasone 50 μg)
Number of subjects: 30
Study 26198280 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 G vitrectomy and circumferential scleral buckling (E1)
Number of subjects: 257
Study 26198280 — intervention group
Group type: COMPARATOR
Intervention: 20 G vitrectomy alone (C)
Number of subjects: 257
Study 26198280 — intervention group
Group type: EXPERIMENTAL
Intervention: 23/25 G vitrectomy alone (E2)
Number of subjects: 257
Study 24371264 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 60
Study 24371264 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 22509949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium treatment
Number of subjects: 30
Study 21120304 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (5 joule/cm² at each point over maximum 5‐6 painful points for 1 minute)
Number of subjects: 52
Study 21120304 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy
Number of subjects: 52
Study 18341614 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-beta
Number of subjects: 0
Study 18341614 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin + Interferon (IFN)-beta
Number of subjects: 0
Study 18341614 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study 16449522 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-methylprednisolone (6MPred) 2 mg/kg per day for 5 consecutive days
Number of subjects: 211
Study 16449522 — intervention group
Group type: COMPARATOR
Intervention: 6MPred 5 mg/kg per day for 10 days
Number of subjects: 211
Study 16449522 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MPred 5 mg/kg per day for 10 days + rabbit anti-thymocyte globulin (ATG, 6.25 mg/kg in 10 days)
Number of subjects: 211
Study 15804077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% CsA and 0.1% dexamethasone for 3 months
Number of subjects: 86
Study 15804077 — intervention group
Group type: COMPARATOR
Intervention: 1% CsA for 3 months
Number of subjects: 86
Study 15804077 — intervention group
Group type: COMPARATOR
Intervention: 0.1% dexamethasone for 3 months
Number of subjects: 86
Study 15804077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-conjunctiva injection of dexamethasone combined with eye drops of 1% CsA and 0.1% dexamethasone
Number of subjects: 86
Study 10959781 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% KTP gel
Number of subjects: 42
Study 10959781 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% KTP gel
Number of subjects: 42
Study 10959781 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% KTP alternate gel
Number of subjects: 42
Study 10959781 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% KTP gel
Number of subjects: 42
Study 10959781 — intervention group
Group type: COMPARATOR
Intervention: 25 mg KTP capsule (positive control)
Number of subjects: 42
Study 8911891 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (twice‐weekly intramuscular injections for 5 weeks; total dose 2500 IU for patients less than 1‐year‐old, 5000 IU for 1‐ to 6‐year‐olds, 10000 IU for 6‐ to 11‐year‐olds)
Number of subjects: 310
Study 8911891 — intervention group
Group type: COMPARATOR
Intervention: Inguinal herniography (to detect patent vaginal process)
Number of subjects: 310
Study 1529280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg three times daily for 14 days
Number of subjects: 106
Study 1529280 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 106
Study 1529280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 106
Study 6732212 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg once a day for 5 days)
Number of subjects: 132
Study 6732212 — intervention group
Group type: COMPARATOR
Intervention: Bacitracin ointment (topically applied three times a day for 10 days)
Number of subjects: 132
Study 6732212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rifampin and bacitracin
Number of subjects: 132
Study 6732212 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 132
Study 30925824 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran supplement containing PRB (43 μg LRA/day)
Number of subjects: 100
Study 30925824 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 100
Study 29960358 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based screening using a grammar variational autoencoder
Number of subjects: 3989
Study 29960358 — intervention group
Group type: COMPARATOR
Intervention: Randomised search
Number of subjects: 3989
Study 27711199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 103
Study 27711199 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 103
Study 25366674 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynocular (used by nurses)
Number of subjects: 932
Study 25366674 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary colposcope (used by nurses)
Number of subjects: 932
Study 25366674 — intervention group
Group type: COMPARATOR
Intervention: Gynocular (used by doctors)
Number of subjects: 932
Study 25366674 — intervention group
Group type: COMPARATOR
Intervention: Stationary colposcope (used by doctors)
Number of subjects: 932
Study 25366674 — intervention group
Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 932
Study 23059159 — intervention group
Group type: EXPERIMENTAL
Intervention: BL-1020 20-30 mg/d
Number of subjects: 363
Study 23059159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 23059159 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2-8 mg/d)
Number of subjects: 363
Study 23059159 — intervention group
Group type: EXPERIMENTAL
Intervention: BL-1020 10 mg/d
Number of subjects: 363
Study 19937166 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical navigation
Number of subjects: 80
Study 19937166 — intervention group
Group type: COMPARATOR
Intervention: Conventional jig‐based technique
Number of subjects: 80
Study 18832540 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer teaching intervention for physicians
Number of subjects: 870
Study 18832540 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 870
Study 16055579 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.125% bupivacaine with 2 microg/mL fentanyl at a rate of 8 mL/h (group A)
Number of subjects: 190
Study 16055579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus of 10 mL of 0.25% bupivacaine on demand (group B)
Number of subjects: 190
Study 16055579 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia (group C)
Number of subjects: 190
Study 12449445 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg/day
Number of subjects: 15
Study 12449445 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 15
Study 12449445 — intervention group
Group type: COMPARATOR
Intervention: Control (no EPA)
Number of subjects: 15
Study 10609824 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal high in monounsaturated fat
Number of subjects: 0
Study 10609824 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich meal
Number of subjects: 0
Study 7815886 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 155
Study 7815886 — intervention group
Group type: COMPARATOR
Intervention: D&C
Number of subjects: 155
Study 1833042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, high-dose cytosine arabinoside, and caffeine (CAC)
Number of subjects: 82
Study 1833042 — intervention group
Group type: COMPARATOR
Intervention: Streptozotocin, mitomycin, and 5-fluorouracil (SMF)
Number of subjects: 82
Study 6120313 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral immunisation with cholera B subunit
Number of subjects: 0
Study 6120313 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular immunisation with cholera B subunit
Number of subjects: 0
Study 6120313 — intervention group
Group type: EXPERIMENTAL
Intervention: Second immunisation by either route (oral or intramuscular)
Number of subjects: 0
Study 30638065 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-plus-fluoxetine
Number of subjects: 0
Study 30638065 — intervention group
Group type: COMPARATOR
Intervention: CBT-plus-placebo
Number of subjects: 0
Study 30638065 — intervention group
Group type: COMPARATOR
Intervention: CBT-only
Number of subjects: 0
Study 30638065 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0